已发表论文

载脂蛋白 C1(APOC1):宫颈癌的新型诊断和预后生物标志物

 

Authors Shi X, Wang J, Dai S, Qin L, Zhou J, Chen Y

Received 7 September 2020

Accepted for publication 26 November 2020

Published 15 December 2020 Volume 2020:13 Pages 12881—12891

DOI https://doi.org/10.2147/OTT.S280690

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Federico Perche

Background: Previous reports showed that APOC1  was associated with several cancers but the function of APOC1  in cervical cancer was unknown. This study aimed to investigate the clinical effect and function of APOC1  in cervical cancer.
Materials and Methods: In this study, the relative expression of APOC1  in cervical cancer was detected by RT-qPCR. In order to determine the cell proliferation and migration and invading ability and apoptosis more accurately, we used CCK8 assay, Edu assay, wound healing assay, migration and invasion assay, flow cytometry assay, co-immunoprecipitation, proteomics and Western blot by silencing and overexpressing APOC1 , respectively. The role of APOC1  on tumor progression was explored in vitro and vivo.
Results: The relative expression of APOC1  in cervical cancer tissues was up-regulated (P< 0.05). In cervical cancer cell lines, silencing of APOC1  restrained cell progression and EMT, while over-expression of APOC1  accelerated cell progression and EMT in vivo and vitro (P< 0.05).
Conclusion: APOC1  acts as an oncogene in cervical cancers and knockdown of APOC1  inhibited cervical cancer cells growth in vitro and in vivo. There is a close relationship between the relative expression of APOC1  and clinical outcome in cervical cancer patients.
Keywords: APOC1 , cervical cancer, progression, prognosis